HC Wainwright Weighs in on TransCode Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:RNAZ)

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) – Investment analysts at HC Wainwright dropped their Q3 2024 earnings estimates for shares of TransCode Therapeutics in a research note issued to investors on Thursday, August 15th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.51) for the quarter, down from their previous forecast of ($0.35). HC Wainwright currently has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($1.98) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($2.05) EPS, FY2025 earnings at ($0.47) EPS, FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.30) EPS and FY2028 earnings at ($0.25) EPS.

TransCode Therapeutics Price Performance

Shares of TransCode Therapeutics stock opened at $0.27 on Monday. The company has a 50 day moving average price of $0.69 and a 200 day moving average price of $0.78. TransCode Therapeutics has a 52 week low of $0.22 and a 52 week high of $128.00.

Hedge Funds Weigh In On TransCode Therapeutics

A hedge fund recently bought a new stake in TransCode Therapeutics stock. Virtu Financial LLC purchased a new position in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned about 0.84% of TransCode Therapeutics at the end of the most recent quarter.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.